Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07126743
Active, not recruiting Observational

Organic Pollutant Build-Up in Body Fat and Stomach Tissue Linked to Obesity Levels

NCT07126743 · tracked via the Priya Life Science China tracker
Sponsor
Dong Peng
Phase
Observational
Started
2025-08-01
Last updated
2025-08-17

Condition(s) studied

Obesity &Amp; Overweight

Investigational drug(s) / intervention(s)

exposure to organic pollutant

exposure to organic pollutant: Small samples of subcutaneous and visceral adipose tissue will be analyzed for the presence and concentration of specific organic pollutants using validated analytical chemistry methods, such as gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS).

Study summary

This study looks at whether certain environmental chemicals, called organic pollutants, build up in the body fat and stomach tissues of people with obesity who are having weight-loss (bariatric) surgery. These pollutants can come from things like plastics, pesticides, or industrial waste, and may affect health in different ways.

The investigators will measure the amount of these pollutants in tissue samples taken during surgery and see if the levels are different in people with mild, moderate, or severe obesity. By understanding these patterns, the investigators hope to learn more about how environmental factors may influence obesity and related health problems. The findings could help guide future prevention and treatment strategies for patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults ≥18 years. * BMI ≥30 kg/m² at screening (measured within 30 days before surgery). * Scheduled for primary bariatric surgery (e.g., sleeve gastrectomy or Roux-en-Y gastric bypass) for clinical indications. * Able to provide informed consent. * Willing to allow intraoperative collection of subcutaneous/visceral adipose tissue and gastric tissue for pollutant analysis. * Availability of basic preoperative clinical data (demographics, comorbidities, relevant labs). Exclusion Criteria: * Prior bariatric or major upper gastrointestinal surgery that alters stomach/anatomy relevant to sampling. * Pregnant or breastfeeding at screening or on day of surgery. * Active malignancy (excluding non-melanoma skin cancers) or ongoing systemic immunosuppressive therapy (e.g., chronic corticosteroids, biologics) within 3 months. * Severe organ dysfunction: decompensated cirrhosis (Child-Pugh C) or eGFR \<30 mL/min/1.73m². * Acute infection or decompensated chronic illness that would preclude elective surgery per treating team. * Documented high-level occupational or accidental chemical exposure within 6 months (e.g., pesticide poisoning) likely to bias tissue pollutant measurements. * Participation in another interventional study expected to affect weight or metabolism within 3 months. * Inadequate tissue obtainable at surgery for analysis (determined intraoperatively by the investigators).

Primary outcome measure(s)

  • Obesity Severity — At baseline (within 1 month before bariatric surgery).
    The investigators will assess obesity severity based on body mass index (BMI), calculated as body weight in kilograms divided by height in meters squared (kg/m²). BMI will be obtained using standardized measurements of height and weight during the preoperative evaluation. Obesity severity will be categorized according to World Health Organization (WHO) criteria (Class I: 30.0-34.9 kg/m², Class II: 35.0-39.9 kg/m², Class III: ≥ 40.0 kg/m²).

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital of Chongqing Medical University Chongqing Chongqing Municipality

More Dong Peng trials in China

Microplastics in Paraneoplastic and Intratumoral for Colorectal Cancer Active, not recruiting
the Effect of Environmental Factors on Colorectal Cancer Based on Macrogenomes Active, not recruiting
The Effect of Environmental Factors on Gastric Cancer Based on Macrogenome Active, not recruiting
Impact of Pre- and Post-operative Serum Metabolome Dynamics in Colorectal Resection Outcomes Active, not recruiting
Impact of Environmental Factors and Metabolomics on Colorectal Cancer. Active, not recruiting

Other trials for the same condition

UBT251 Injection Phase II Clinical Study (CKD) Recruiting
Phase Ib Clinical Study on the Efficacy and Safety of MDR-001 in Patients Who Are Obesity or Overweight Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07126743 on ClinicalTrials.gov ↗ ← All trials in China